Facebook
X
LinkedIn
ForwardDate & Time of Session - 2/4/26 - from 2:30 - 3:30PM
Overview
In August 2025, subcutaneous semaglutide (Wegovy®) became only the second medication to receive FDA approval for the treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). This approval is contingent upon confirmation of clinical benefit in an ongoing trial, with results anticipated in 2028. As subcutaneous semaglutide’s indications expand, pharmacists play a critical role in identifying appropriate patient populations, understanding therapeutic considerations, and managing dosing titration. This presentation will provide an overview of MASH, current treatment options, and the pivotal clinical trial that supported subcutaneous semaglutide’s new indication.
Objectives
Upon completion of this activity, the participant will be able to:
1. Describe the rationale for the nomenclature change from NASH to MASH and its clinical implications
2. Compare current and emerging treatment options for the management of MASH
3. Identify patient eligibility criteria for subcutaneous semaglutide in the treatment of MASH, including dosing considerations
Target Audience
Pharmacists, physicians, nurses, fellows and residents
Speaker
Kaiá Harrison, PharmD
PGY2 Ambulatory Care Pharmacy Resident
Norton Children’s Hospital
Louisville, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC (UK Healthcare CECentral)
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).
- 1.00 IPCE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.